Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its targeted protein degrader ICP-490. The drug is approved for use in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and other hematological malignancies.
Drug Profile
ICP-490, developed through InnoCare’s molecular glue platform, works by inducing the ubiquitination and degradation of the lymphatic transcription factors Ikaros and Aiolos. It does this by specifically binding to the substrate receptor CRBN of the CRL4CRBN-E3 ubiquitin ligase complex. This process leads to the induction of apoptosis and inhibits the survival and proliferation of tumor cells. Additionally, ICP-490 can stimulate T cell activation, release interleukin IL-2, enhance the function of effector T cells, and exert immunomodulatory effects.-Fineline Info & Tech
